GeoVax Labs, Inc.
GOVX · XNASCIK 832489fmd_0GNSXTQ5W5PPC4RZJY35HYQB7XManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2001 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 4 | 2 |
| Research and development | 2 | 2 | 2 | 2 | 2 | 16 | 9 | 21 | 24 | 18 |
| Total operating expenses | 4 | 3 | 4 | 4 | 5 | 19 | 14 | 27 | 29 | 24 |
| Operating income | (3) | (2) | (3) | (2) | (3) | (19) | (14) | (27) | (25) | (22) |
| Interest expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 1 | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | 0 |
| Net income | (3) | (2) | (3) | (2) | (3) | (19) | (14) | (26) | (25) | (21) |